• City of Hope flagged new clinical findings slated for presentation at the 2026 ASCO Annual Meeting in Chicago from May 29 to June 2, highlighting several early- to late-stage oncology studies.
• A kidney cancer analysis found that adding a live microbiome therapy to standard immunotherapy was associated with better patient responses, supporting the microbiome as a potential tool to guide treatment choice.
• In relapsed or refractory large B-cell lymphoma, updated SUNMO trial results showed a bispecific antibody regimen outperformed standard chemotherapy, strengthening its positioning as an alternative for transplant-ineligible patients.
• An early liver cancer study of a first-in-class Wnt-pathway inhibitor showed signs of activity in molecularly selected patients, indicating a possible new targeted option in a hard-to-treat segment.
• A first-in-human prostate cancer study reported early tumor and PSA responses for a dual-targeting antibody-drug conjugate in heavily pretreated patients, supporting continued dose optimization and development.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. City of Hope published the original content used to generate this news brief on May 21, 2026, and is solely responsible for the information contained therein.